Company context
The company provides inspection, prevention, treatment and monitoring services across a distributed customer base. Delivery depends on trained field personnel, appropriate treatment selection, controlled chemical custody, accurate site records, safe application, follow-up effectiveness and reliable scheduling. The service promise is preventive and evidence-led: a completed visit is not valuable if the underlying source, pathway or recurrence risk remains unaddressed.
The business is preparing its governance, systems and disclosures for a potential public listing. Its recurring contracts and route-based model can appear predictable while hiding contract leakage, repeat visits, technician vacancies, unbilled scope, ineffective treatments, chemical variance, customer churn or unsafe shortcuts. The Board seeks an Independent Director who can turn field evidence into reliable Board oversight and ensure that growth never compromises human, animal or environmental safety.
The Board mandate
The Director will strengthen governance of chemical stewardship, service protocols, technician competence, route economics, customer contracting, digital service records, product claims, procurement, complaints and IPO metrics. The appointee must distinguish genuine recurring revenue from contracts that require uneconomic rework, carry unclear outcome promises or are retained through pricing that does not cover safe delivery.
The role requires comfort with a dispersed frontline workforce and thousands of small operating decisions. Policies designed at head office must be tested under time pressure at customer sites. The Director should insist that technicians can stop unsafe work, record adverse conditions and escalate customer non-compliance without fear of losing incentives.
Strategic and governance responsibilities
-
Establish chemical stewardship. Review approved products, procurement, batch traceability, storage, dilution, issue, return, container disposal and reconciliation. Restricted or expired materials must be quarantined and independently investigated.
-
Protect treatment selection. Ensure site assessment, infestation evidence, risk classification and non-chemical controls precede treatment. Product choice, dose and frequency should follow approved protocols rather than sales preference or technician habit.
-
Assure workforce competence. Govern induction, supervised practice, periodic assessment, specialised authorisation, protective equipment, occupational health and refresher training. Attendance at training should not be treated as proof of competence.
-
Strengthen service-record integrity. Require reliable time, location, treatment, material, observation, customer acknowledgement and follow-up data. Prevent retrospective completion, shared credentials and automated closure of visits that did not occur.
-
Measure treatment effectiveness. Track recurrence, callbacks, repeat applications, unresolved structural causes and customer adherence to recommendations. Completed jobs and chemical consumption are poor substitutes for outcome quality.
-
Make contract economics visible. Include technician time, travel, equipment, monitoring devices, chemical, protective equipment, supervision, repeat visits, customer reporting, complaint resolution and receivable days.
-
Improve route productivity responsibly. Optimise density, sequencing and utilisation while preserving inspection quality, safe preparation, travel realism and required dwell time. Productivity targets must not encourage skipped controls or falsified records.
-
Govern customer commitments. Review guarantees, response times, exclusions, access obligations, structural remediation, reporting, liability and termination. Marketing should not promise permanent outcomes where environmental conditions remain outside company control.
-
Protect sensitive environments. Establish enhanced review for sites involving food, children, vulnerable persons, animals, water, enclosed spaces or continuous operations. Treatment and escalation protocols should reflect consequence, not only contract value.
-
Strengthen procurement and equipment controls. Examine supplier qualification, product authenticity, dispensing equipment, monitoring devices, calibration, protective gear and vehicle storage. Commercial rebates must not bias technical selection.
-
Govern complaints and incidents. Classify exposure, illness, contamination, property damage, treatment failure, employee conduct and record-integrity allegations. Serious cases require independent investigation, evidence preservation and timely notification.
-
Build scalable acquisition controls. For regional acquisitions, assess permits, chemical inventory, workforce competence, customer claims, environmental practices, undocumented liabilities, data quality and owner dependence before valuation.
-
Prepare IPO-grade metrics. Standardise active contracts, recurring revenue, renewal, churn, route density, technician productivity, repeat visits, complaint rates, safety incidents and collected contribution. Historical definitions must be reconciled.
-
Stress-test resilience. Model chemical withdrawal, supplier interruption, severe incident, technician shortage, customer loss, regulatory change, failed acquisition integration, cyber outage and mass complaint or refund demand.
Decisions expected at Board level
The Director will contribute to new service categories, entry into additional regions, acquisitions, central warehousing, route technology, connected-monitoring devices, high-risk customer contracts, chemical partnerships, insurance limits, capital structure and timing of the proposed IPO.
Every expansion paper should identify the competence required, chemical and equipment controls, route density, supervision ratio, service-level liability, working capital, customer concentration and downside exit plan. Acquisition approval should be conditional on verified chemical custody, employee records, incident history, customer-contract quality and a funded control-integration programme.
Audit, safety and IPO-readiness agenda
The Board dashboard should cover scheduled and completed services; record exceptions; callbacks and recurrence; chemical consumption variance; restricted inventory; technician certification; safety exposures; customer complaints; response-time breaches; contract contribution; churn; receivable ageing; route productivity; acquisition controls migrated; audit findings; and IPO-remediation milestones.
Internal audit should include surprise chemical counts, route observation, service-record verification with customers, dilution and equipment checks, complaint-file review, payroll-to-field reconciliation and contract-to-invoice testing. Serious exposure, record falsification or unauthorised chemical use must reach the Independent Director promptly, irrespective of confirmed financial impact.
Candidate profile
Candidates should have at least 22 years of senior leadership across environmental services, facilities services, field operations, food safety, public health, chemicals, occupational safety, consumer services, audit, finance or multi-location governance. Former CEOs, COOs, CFOs, safety leaders, service-network heads, quality executives, Audit Committee Chairs and experienced pre-IPO directors may be suitable.
The successful candidate need not be a technical pest specialist but must be capable of learning the treatment-risk framework, testing field evidence and defending investment in competence and safe delivery. Experience with route businesses, frontline workforces, recurring contracts, regulated products, acquisitions or institutional transactions will be valuable.
Eligibility, independence and conflicts
Active inclusion in the IICA Independent Directors Databank is mandatory, notwithstanding the company's current unlisted status. The candidate must be capable of meeting listed-company independence standards before the formal offer process. Interests involving chemical suppliers, equipment vendors, facilities companies, major customers, insurers, lenders, investors, auditors, acquisition targets or competing service networks must be disclosed.
The appointee must remain independent of founders, financial investors and management. The role may not be used to place products, insurance, technology, consulting or transaction services with the company.
First 100-day priorities
- Accompany field teams across different service environments and review non-routine treatments.
- Trace selected chemical batches from procurement through use, return and disposal.
- Examine treatment failures, safety events, customer complaints and service-record exceptions.
- Reconstruct full economics for major contracts and recently lost or repriced contracts.
- Test proposed IPO metrics against source systems and stable definitions.
- Recommend Board escalation thresholds for safety, chemical, conduct and data-integrity matters.
First-year outcomes
The first year should deliver verifiable service records, stronger chemical custody, competence-based technician authorisation, outcome-led quality measures, disciplined contract economics and investor metrics supported by source evidence. The company should be able to grow without asking frontline employees, customers or the environment to absorb hidden costs.